
MD-HIP

Medical Device with type I Collagen of porcine origin
Reduces pain, improves hip mobility, and supports periarticular muscle structures



SCAN ME

Medical Device CE (class III). Read the instructions and warnings before use.

COMPOSITION
Collagen of porcine origin, Calcium Phosphate, NaCl, Water for injection.

PACKAGE
Box of 10 vials (single vial 2 ml – extraction volume).

INJECTION ROUTES OF ADMINISTRATION
Periarticular and intraarticular.

SUGGESTED NEEDLES
- Periarticular: 26G x 30 mm needle.
- Intraarticular: 20G x 90 mm needle.

Note: Disinfect the skin thoroughly with iodopovidone or chlorhexidine.

INJECTION TECHNIQUES OF ADMINISTRATION
- **Periarticular administration:** insert the needle near the joint to a depth of 13-25 mm.
- **Intraarticular administration:** insert the needle into the anterior recess of the capsule at the level of the femoral head through an antero-superior or antero-inferior approach. When the 40-60 mm needle is in contact with the femoral head, retract 1-2 mm and inject into the hip joint cavity.

MAIN INDICATIONS
MD-HIP is designed to improve hip motion, helping to contain physiological joint and tissue deterioration.

Scientific evidence shows the efficacy and safety of MD-HIP in cases of:
- Coxarthrosis
- Coxalgia:
  - of muscular and/or nerve origin
  - due to prolonged bed rest
  - due to aging
  - due to bad posture
  - due to concomitant chronic diseases
  - due to traumas and injuries.

Treatment can be combined with other therapies.

THERAPEUTIC PROTOCOL:
1-2 infiltrations per week to contain physiological or pathological deterioration of the hip.
Results are evident from the third week but, depending on the patient's clinical situation, it is possible to continue treatment up to the tenth week without risk.

REFERENCES

- *Boccaccio S. Treatment Of Hip Osteoarthritis With Md-hip – Clinical And Functional Evaluation Using A Gait Analysis System. Physiological Regulating Medicine, 2021;37-41.*
- *Milano E. The role of MD-HIP In ultrasound-guided injection therapy for osteoarthritis of the hip. Physiological Regulating Medicine, 2018;3-8.*
- *Ottaviani M. Treatment of joint conditions with Guna Collagen Medical Devices – Clinical study on 257 patients. Physiological Regulating Medicine, 2018; 19-28.*
- *Giovannangeli F. Intra articular administration of MD HIP in 24 patients affected by symptomatic hip osteoarthritis – a 24-month cohort study. Physiological Regulating Medicine, 2017;31-2.*
- *Tivchev P. Efficacy of collagen injections Guna MD-HIP and Guna MD-MATRIX in treatment of coxarthrosis – Clinical and ultrasonographic examination. Ortopediya i Travmatologiya (Bulgarian Journal of Orthopedics and Trauma), 2012;3(49):123-8.*
- *Migliore A. et al. Intra-articular administration of MD-HIP in 7 patients affected by ostheoarthritis unresponsive to viscosupplementation – six-month multicenter trial. Poster presented at the International Symposium of Intra-articular treatment (ISIAT), Rome (IT), October 2011. Physiological Regulating Medicine. 2013; 31.*

For article consultation: collagenmd.guna.com

INFORMATION RESERVED FOR HEALTHCARE PROFESSIONALS

Medical device CE 0373

Guna S.p.a. has joined
Lifegate's Zero® Impact project
To offset its plant's CO_2 emissions
by contributing to the development
of energy efficiency and forest protection initiatives.

GUNA medical device
Guna S.p.a. • Milano
collagenmd.guna.com

GUNA S.p.a. is a company with quality management standard system ISO 13485 certified by Bureau Veritas Italia SpA

7EX100 B